Baiaosetu (688796.SH) issued an advance increase. Net profit for the semi-year is expected to be 236 million yuan to 246 million yuan, an increase of 391.87% to 412.71% over the previous year

Zhitong Finance App News, Baiaosetu (688796.SH) announced that the company expects to achieve net profit of 236 million yuan to 246 million yuan in the half year of 2026, an increase of 391.87% to 412.71% over the previous year.

As the biomedical industry enters a new stage of innovation leading industrial development, the company relies on forward-looking research and development, leading products and high-quality services, and a high-quality customer network covering the world's top pharmaceutical companies and leading biotech companies to fully unleash its competitive advantage and deeply embrace the business development opportunities brought about by the rise in industry prosperity. During the reporting period, the company's two major business lines achieved two-wheel drive and leapfrog collaboration, driving continuous rapid growth in revenue.

Relying on the significant increase in the company's revenue scale and position in the industry, the scale effect of the company's production capacity and operation is showing at an accelerated pace. On this basis, combined with the continuous deepening of superimposed lean management, the company effectively reduced costs and increased efficiency, driving a further increase in overall gross margin, effectively reducing the cost ratio during the period, significantly increasing the company's profitability, and accelerating the release of large-scale profits.